Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 69.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,403 shares of the biotechnology company’s stock after selling 49,668 shares during the period. Baillie Gifford & Co.’s holdings in Ascendis Pharma A/S were worth $3,196,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ASND. Price T Rowe Associates Inc. MD boosted its position in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after buying an additional 4,338 shares in the last quarter. Evolutionary Tree Capital Management LLC grew its position in Ascendis Pharma A/S by 82.3% in the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after buying an additional 11,223 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Ascendis Pharma A/S by 221.0% in the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 4,205 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after acquiring an additional 234,446 shares during the last quarter.

Analyst Upgrades and Downgrades

ASND has been the topic of a number of recent research reports. Wells Fargo & Company lifted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Wedbush raised Ascendis Pharma A/S to a “strong-buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, November 4th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Finally, JPMorgan Chase & Co. cut their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $195.92.

Ascendis Pharma A/S Trading Down 1.3 %

NASDAQ ASND opened at $126.03 on Thursday. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The firm’s fifty day simple moving average is $132.04 and its 200-day simple moving average is $132.86. The company has a market capitalization of $7.64 billion, a PE ratio of -13.54 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, analysts predict that Ascendis Pharma A/S will post -7.35 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.